These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34675120)

  • 1. HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.
    Osada T; Crosby EJ; Kaneko K; Snyder JC; Ginzel JD; Acharya CR; Yang XY; Polascik TJ; Spasojevic I; Nelson RC; Hobeika A; Hartman ZC; Neckers LM; Rogatko A; Hughes PF; Huang J; Morse MA; Haystead T; Lyerly HK
    Mol Cancer Ther; 2022 Jan; 21(1):217-226. PubMed ID: 34675120
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Osada T; Kaneko K; Gwin WR; Morse MA; Hobeika A; Pogue BW; Hartman ZC; Hughes PF; Haystead T; Lyerly HK
    Clin Cancer Res; 2017 Dec; 23(24):7531-7542. PubMed ID: 28993342
    [No Abstract]   [Full Text] [Related]  

  • 3. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
    He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
    Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells.
    Eguchi T; Sogawa C; Ono K; Matsumoto M; Tran MT; Okusha Y; Lang BJ; Okamoto K; Calderwood SK
    Cells; 2020 Mar; 9(3):. PubMed ID: 32204513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.
    Ni L; Yang CS; Gioeli D; Frierson H; Toft DO; Paschal BM
    Mol Cell Biol; 2010 Mar; 30(5):1243-53. PubMed ID: 20048054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
    Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
    Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.
    Nolan KD; Franco OE; Hance MW; Hayward SW; Isaacs JS
    J Biol Chem; 2015 Mar; 290(13):8271-82. PubMed ID: 25670862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer.
    Leav I; Plescia J; Goel HL; Li J; Jiang Z; Cohen RJ; Languino LR; Altieri DC
    Am J Pathol; 2010 Jan; 176(1):393-401. PubMed ID: 19948822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
    Kang BH; Siegelin MD; Plescia J; Raskett CM; Garlick DS; Dohi T; Lian JB; Stein GS; Languino LR; Altieri DC
    Clin Cancer Res; 2010 Oct; 16(19):4779-88. PubMed ID: 20876793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.
    Gillis JL; Selth LA; Centenera MM; Townley SL; Sun S; Plymate SR; Tilley WD; Butler LM
    Oncotarget; 2013 May; 4(5):691-704. PubMed ID: 23674566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound-targeted microbubble destruction combined with dual targeting of HSP72 and HSC70 inhibits HSP90 function and induces extensive tumor-specific apoptosis.
    Wang H; Song Y; Hao D; Bai M; Jin L; Gu J; Su Y; Liu L; Jia C; Du L
    Int J Oncol; 2014 Jul; 45(1):157-64. PubMed ID: 24736948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
    Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
    Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The co-chaperone p23 promotes prostate cancer motility and metastasis.
    Cano LQ; Lavery DN; Sin S; Spanjaard E; Brooke GN; Tilman JD; Abroaf A; Gaughan L; Robson CN; Heer R; Mauri F; de Rooij J; Driouch K; Bevan CL
    Mol Oncol; 2015 Jan; 9(1):295-308. PubMed ID: 25241147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development.
    Lisanti S; Garlick DS; Bryant KG; Tavecchio M; Mills GB; Lu Y; Kossenkov AV; Showe LC; Languino LR; Altieri DC
    J Biol Chem; 2016 Nov; 291(48):25247-25254. PubMed ID: 27754870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
    Moses MA; Henry EC; Ricke WA; Gasiewicz TA
    Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
    Nassar ZD; Mah CY; Centenera MM; Irani S; Sadowski MC; Scott JS; Nguyen EV; Nagarajan SR; Moldovan M; Lynn DJ; Daly RJ; Hoy AJ; Butler LM
    Mol Cancer Res; 2020 Oct; 18(10):1500-1511. PubMed ID: 32669400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell surface heat shock protein 90 modulates prostate cancer cell adhesion and invasion through the integrin-β1/focal adhesion kinase/c-Src signaling pathway.
    Liu X; Yan Z; Huang L; Guo M; Zhang Z; Guo C
    Oncol Rep; 2011 May; 25(5):1343-51. PubMed ID: 21369706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
    Eskew JD; Sadikot T; Morales P; Duren A; Dunwiddie I; Swink M; Zhang X; Hembruff S; Donnelly A; Rajewski RA; Blagg BS; Manjarrez JR; Matts RL; Holzbeierlein JM; Vielhauer GA
    BMC Cancer; 2011 Oct; 11():468. PubMed ID: 22039910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.